It didn’t sound like a dealbreaker, so she decided to try it.Two weeks after her third dose, Aaron was dead.She died last ...
With two years of experience selling Alzheimer’s disease antibody Leqembi so far under Eisai’s belt, the Japanese drugmaker ...
There are glimmers of hope, however, with Eisai reporting last month that it is on track to meet that fiscal 2024 sales ...
Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...
The European Union's drugs regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's small impact on ...
The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of ...
According to Eisai's simulation, Leqembi sales will reach JPY 250 to 280 billion for their financial year (FY) 2027, which ends in March 2028. Eisai's presentation can be found on https://www ...
The European Medicines Agency committee declined to approve Eli Lilly's Alzheimer’s treatment, citing risks of brain bleeding ...
BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi. According to Eisai's simulation, Leqembi ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback